ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INDV Indivior Plc

1,408.00
8.00 (0.57%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BN4HT335 ORD USD0.50
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  8.00 0.57% 1,408.00 1,403.00 1,414.00 1,426.00 1,365.00 1,400.00 660,233 16:35:05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.09B 2M 0.0148 952.03 1.91B
Indivior Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 1,400p. Over the last year, Indivior shares have traded in a share price range of 1,128.00p to 1,927.00p.

Indivior currently has 135,272,708 shares in issue. The market capitalisation of Indivior is £1.91 billion. Indivior has a price to earnings ratio (PE ratio) of 952.03.

Indivior Share Discussion Threads

Showing 4301 to 4323 of 4425 messages
Chat Pages: 177  176  175  174  173  172  171  170  169  168  167  166  Older
DateSubjectAuthorDiscuss
20/11/2023
07:58
Should see some buying today. Share purchase programme starts. GLA
youngers
17/11/2023
16:58
Personally I would rather see cash re-deployed in the business than simply propping up the share price short-term with share buybacks. Maybe more bolt-on acquisitions to further diversify revenues?

I understand and appreciate management's confidence in cashflow and growth prospects, but the cash pile has taken quite a hit in the last two years (with a few payments still yet to be made). I would prefer cash conservation and balance sheet flexibility to buybacks. Even a dividend or two wouldn't go amiss!

redwing1
17/11/2023
15:43
Yes today's announcements are positive and have probably steadied the shareholder boat- its a view! However read between the lines and just quite possibly one can start to comprehend what has been happening!

Also,there is a new biggish shareholder, Madison Partners LP . I say new as I cannot trace them as shareholders previously but do check, maybe that's me!

If it is a new shareholder then we haven't quite seen the full story yet as the stock has come from somewhere. I suspect today's announcements tell some of the story but not quite all. Could it possibly be Scopia's revised shareholding agreement has already been acted upon?

Whatever has been driving the recent share price weakness and the above maybe well wide of the mark!, today's statements on trading , prospects etc and the proposed major share buy back program have reassured me in quite a big way. Doesn't mean to say I am right!

gregmorg
17/11/2023
14:12
Doesn’t get much more confident than this:

“Given our confidence in delivering on the medium-term profitable growth profile we outlined at our capital markets day last December, the Board of Directors and management team believe that the Company's shares represent an attractive investment opportunity," said Mark Crossley, Chief Executive Officer. "Our expected strong cash flow over this period provides us the ability to reinvest in our business, progress our pipeline, and to take this action to deliver direct shareholder returns."

youngers
17/11/2023
12:34
That’s great news. I think mgmt probably a bit surprised by the reaction to removing all the legal hangover and then the results announcement.

Expecting a big push at q4 results to set out a compelling vision for the future with significant profitability to drive a re rating in this stock

youngers
17/11/2023
12:22
Good news. market is however so dysfunctional that there is no buying
dealy
17/11/2023
12:09
RNS...... share buy back announcement!!
pngasef
15/11/2023
14:03
volume is very low
dealy
15/11/2023
11:14
Biggest faller on the FTSE350 today. Quite an achievement...
liam1om
14/11/2023
19:58
Yeah. I got fomo after missing out on the 100 point or so jump. I'll be in the red by Friday I think.
casholaa
14/11/2023
15:50
Buyers are back now though, happy days.
pngasef
14/11/2023
08:05
This sell off has taken place without any announced reduction in holdings by large holders.
dealy
13/11/2023
08:58
I make that 7 down days in a row. Worst run its had in a long time and again in the top three biggest losers on the FTSE350. Crazy.
liam1om
12/11/2023
12:01
Its noticeable that second line stocks,especially those that don't pay a dividend,are getting particularly badly hit in these markets.It could be a function of the 'risk free' interest now readily available elsewhere but combined with a general risk aversion,a lot of stocks are vulnerable.Anyway,Indivior isn't alone.
steeplejack
10/11/2023
17:12
Over the last 3 years or so, my stops have kicked in at least 3 times. I've learnt it gives way a lot when it moves in either direction.
casholaa
10/11/2023
16:43
Well I listened quite intensely to the company and to the Q and A which can highlight any added theme but didn’t get any unknowns popping up . Maybe the bears in this market are the only active participants!
gregmorg
10/11/2023
16:43
Well I listened quite intensely to the company and to the Q and A which can highlight any added theme but didn’t get any unknowns popping up . Maybe the bears in this market are the only active participants!
gregmorg
10/11/2023
16:16
Steeplejack - I don't think the post from ShearClass does sum things up very well. They are wide of the mark with suboxone because the entry of a 4th generic competitor has been pushed back later in the year more than once and hence suboxone sales have held up ok. The generic competition is already well known and is becoming less relevant each quarter as Sublocade grows. Sublocade and Perseris will account for at least $645m out of a total c$1050m sales this year.

Perseris guidance is a small negative but not that significant and I suspect it is too early to talk about the Opvee launch.

The impact of the recent legal settlement on the balance sheet should be well known and still leaves Indivior with net cash to pay the remaining DOJ instalments.

Something has obviously spooked the institutions from the conference call but I can't fathom what. Looks oversold to me.

redwing1
10/11/2023
16:00
Am right in thinking that the total liabilities and provisions at the moment equate to $880 million. $440m provisions (DP class settlement etc) and $440m liabilities (DOJ. etc). Cash $610 m (plus $160m in investments).
Thanks.

elsa7878
10/11/2023
13:54
Listened to the webcast and everything seemed Okay but nothing more than that-- didn't have a buzz, one was or the other, at the end of it.

I admit I did think it could drift for a while as there was no added aspect that one could focus on. Not the first time with Indivior's 3rd quarter results that I recall.

Perseris sales, from a low overall group base were fine that I can see - very much in line but the annual guidance was adjusted to a lower end of earlier projected range because of some new competing product launch but appeared no big deal. Longer term hopes still very positive. Yet product potential not big in the context of the whole. Sublocade growth going along well.

Added costs and provisions were to be expected so a 3rd quarter loss was inevitable.My take is these overall markets take no prisoners and an element of throwing in the towel and capitulation is upon us. Historically that's often an interesting time. Not enjoying this after the years and years of tribulations but we will see.

gregmorg
10/11/2023
11:26
I've taken this from LSE.Post by ShearClass.It sums things up succinctly i think. I suspect it's due to a multitude of factors; - Sublingual revenues seeing a rapid decline YoY, offsetting Sublocade increases - Below expectations performance of Perseris - No detail on Opvee launch / revenue expectations - Market digesting the balance sheet impact of the massive final settlement & not liking what it sees Ultimately, operating profit is running at ~$225m PA, what we don't know is how much of that is related to sublingual. If revenues continue to decline there as expected, then without a major Opvee launch the top line growth will stall. Essentially things are in the balance, however sentiment has turned negative due to the above factors. Downtrend support sits at ~£11.80 as far as I se
steeplejack
10/11/2023
11:11
Not a holder but must be a broker downgrade. Selling started as the conference call started yesterday so must be something that was said.
elsa7878
10/11/2023
08:19
Second biggest faller on the FTSE350 today. Amazing.
liam1om
Chat Pages: 177  176  175  174  173  172  171  170  169  168  167  166  Older

Your Recent History

Delayed Upgrade Clock